Feilong Qi

632 total citations · 1 hit paper
15 papers, 467 citations indexed

About

Feilong Qi is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Feilong Qi has authored 15 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Molecular Biology and 3 papers in Immunology. Recurrent topics in Feilong Qi's work include Cancer Immunotherapy and Biomarkers (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers) and Extracellular vesicles in disease (2 papers). Feilong Qi is often cited by papers focused on Cancer Immunotherapy and Biomarkers (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers) and Extracellular vesicles in disease (2 papers). Feilong Qi collaborates with scholars based in China, Australia and Singapore. Feilong Qi's co-authors include Guangjun Nie, Zefang Lu, Suping Li, Bozhao Li, Tianjiao Chu, Jingyan Wei, Mengxue Dong, Kudelaidi Kuerban, Yinlong Zhang and Feng Zhao and has published in prestigious journals such as Nano Letters, Nature reviews. Cancer and ACS Applied Materials & Interfaces.

In The Last Decade

Feilong Qi

14 papers receiving 464 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The dynamic role of platelets in cancer progression and their therapeutic implications

2023 86 citations Suping Li, Zefang Lu et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Feilong Qi China	11	182	151	124	121	77	15	467
Yucheng Xiang China	14	253 1.4×	130 0.9×	84 0.7×	111 0.9×	77 1.0×	38	537
May Lin Yap Australia	11	189 1.0×	153 1.0×	72 0.6×	73 0.6×	63 0.8×	13	560
Saini Setua United States	12	248 1.4×	118 0.8×	231 1.9×	123 1.0×	55 0.7×	24	595
Ouri Schwob Israel	11	176 1.0×	104 0.7×	98 0.8×	125 1.0×	42 0.5×	20	503
Chenming Zou China	10	185 1.0×	163 1.1×	74 0.6×	129 1.1×	54 0.7×	15	392
Lauren Price United States	13	210 1.2×	127 0.8×	153 1.2×	148 1.2×	54 0.7×	22	582
Sergio Occhipinti Italy	15	316 1.7×	133 0.9×	94 0.8×	155 1.3×	125 1.6×	32	694
Putty‐Reddy Sudhir Taiwan	11	316 1.7×	96 0.6×	114 0.9×	61 0.5×	76 1.0×	16	702
Kuo‐Hsiang Chuang Taiwan	14	321 1.8×	126 0.8×	79 0.6×	136 1.1×	72 0.9×	32	605
Jindian Li China	14	136 0.7×	134 0.9×	96 0.8×	48 0.4×	55 0.7×	33	487

Countries citing papers authored by Feilong Qi

Since Specialization

Citations

This map shows the geographic impact of Feilong Qi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feilong Qi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feilong Qi more than expected).

Fields of papers citing papers by Feilong Qi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feilong Qi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feilong Qi. The network helps show where Feilong Qi may publish in the future.

Co-authorship network of co-authors of Feilong Qi

This figure shows the co-authorship network connecting the top 25 collaborators of Feilong Qi. A scholar is included among the top collaborators of Feilong Qi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feilong Qi. Feilong Qi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Wu, Zhouliang, Zefang Lu, Feilong Qi, et al.. (2025). Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of PD-1 blockade therapy. Cell Reports Medicine. 6(3). 101984–101984.

Zhang, Xiuping, Bozhao Li, Zefang Lu, et al.. (2023). Nanoparticle-based combination of LMWH and doxorubicin for the efficient treatment of hepatocellular carcinoma with portal vein tumor thrombus. Nano Today. 49. 101787–101787. 6 indexed citations

Li, Suping, Zefang Lu, Tianjiao Chu, et al.. (2023). The dynamic role of platelets in cancer progression and their therapeutic implications. Nature reviews. Cancer. 24(1). 72–87. 86 indexed citations breakdown →

Li, Bozhao, Zefang Lu, Zhenlin Yang, et al.. (2023). Monitoring circulating platelet activity to predict cancer-associated thrombosis. Cell Reports Methods. 3(7). 100513–100513. 6 indexed citations

Li, Fenfen, Jingyi Sun, Xiaoyu Cheng, et al.. (2023). The Combination of Sinusoidal Perfusion Enhancement and Apoptosis Inhibition by Riociguat Plus a Galactose-PEGylated Bilirubin Multiplexing Nanomedicine Ameliorates Liver Fibrosis Progression. Nano Letters. 23(10). 4126–4135. 16 indexed citations

Li, Bozhao, Xiuping Zhang, Zhouliang Wu, et al.. (2022). Reducing Postoperative Recurrence of Early‐Stage Hepatocellular Carcinoma by a Wound‐Targeted Nanodrug. Advanced Science. 9(20). e2200477–e2200477. 34 indexed citations

Wu, Zhouliang, Feilong Qi, Bozhao Li, et al.. (2022). Identification of protein kinase C beta as a therapeutic target for neuroendocrine prostate cancer and development of a nanoparticle-based therapeutic strategy. Nano Today. 48. 101705–101705. 3 indexed citations

Wu, Han, Tian Xia, Feilong Qi, et al.. (2022). A Cleavable Self-Inclusion Conjugate with Enhanced Biocompatibility and Antitumor Bioactivity. CCS Chemistry. 5(4). 823–829. 12 indexed citations

Wu, Han, Hua Wang, Feilong Qi, et al.. (2021). An Activatable Host–Guest Conjugate as a Nanocarrier for Effective Drug Release through Self-Inclusion. ACS Applied Materials & Interfaces. 13(29). 33962–33968. 22 indexed citations

10.

Li, Bozhao, Tianjiao Chu, Jingyan Wei, et al.. (2021). Platelet-Membrane-Coated Nanoparticles Enable Vascular Disrupting Agent Combining Anti-Angiogenic Drug for Improved Tumor Vessel Impairment. Nano Letters. 21(6). 2588–2595. 125 indexed citations

11.

Li, Bozhao, Jingyan Wei, Chunzhi Di, et al.. (2020). Molecularly engineered truncated tissue factor with therapeutic aptamers for tumor-targeted delivery and vascular infarction. Acta Pharmaceutica Sinica B. 11(7). 2059–2069. 18 indexed citations

12.

Qi, Feilong, Meifang Wang, Bozhao Li, et al.. (2020). Reversal of the immunosuppressive tumor microenvironment by nanoparticle-based activation of immune-associated cells. Acta Pharmacologica Sinica. 41(7). 895–901. 30 indexed citations

13.

Qi, Feilong, Chen Zhang, Shanshan Jiang, et al.. (2019). S-ethyl ethanethiosulfinate, a derivative of allicin, induces metacaspase-dependent apoptosis through ROS generation in Penicillium chrysogenum. Bioscience Reports. 39(6). 10 indexed citations

14.

Wang, Yongbin, Qian Wang, Kudelaidi Kuerban, et al.. (2019). Colonic electrical stimulation promotes colonic motility through regeneration of myenteric plexus neurons in slow transit constipation beagles. Bioscience Reports. 39(5). 10 indexed citations

15.

Dong, Mengxue, Zhefeng Meng, Kudelaidi Kuerban, et al.. (2018). Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell Death and Disease. 9(10). 1039–1039. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact